rejuvant life tabs
rejuvant life tabs

Investment

Gerostate Alpha opens crowdfunded capital raise

Buck Institute-founded start-up Gerostate Alpha seeks to crowdfund its biotech platform. When Y Combinator so likes your ideas, it gives...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

AgeX reports fourth quarter and annual 2020 results

Biotech AgeX leverages Juvenescence support to develop diabetes, regeneration and cancer research. California-based AgeX Therapeutics, Inc, a biotech developing therapeutics for human aging and regeneration,...

Latest news

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

Longevity supplements report: Youth & Earth profile

Youth & Earth is keeping it natural, while slowing down aging. Over the coming weeks, we will be bringing you extracts of 11 company profiles...

Longevity supplements report: Juvenescence profile

Ahead of the launch of its first major product, Metabolic Switch, we take a look at Juvenescence. Over the coming weeks, we will be bringing...

Longevity supplements report: ChromaDex profile

We dive into ChromaDex: the company behind the successful nicotinamide riboside supplement Tru Niagen®. Over the coming weeks, we will be bringing you extracts of...

AgeX reports fourth quarter and annual 2020 results

Biotech AgeX leverages Juvenescence support to develop diabetes, regeneration and cancer research. California-based AgeX Therapeutics, Inc, a biotech developing therapeutics for human aging and regeneration,...

New investor offers funding to healthy aging innovators

A fifth investor has joined UK Research and Innovation (UKRI), providing matched funding for top small innovators to develop ideas for healthy aging. The new...

Nerve regeneration tech targets Alzheimer’s and Nasdaq

NervGen readies for NASDAQ listing and clinical trials of lead compound for nerve regeneration in 2021. With a unique nerve regeneration technology, Canadian biotech NervGen...

Cutting longevity drugs development from 15 years to one

Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer's and other age-related diseases. With a focus on...

AgeTech fund: focus on over-50s not millennials

Founding partner of 1843 Capital targets AgeTech investment opportunities with $13 million fund. Connecticut-based early stage investment firm 1843 Capital values diversity highly, and seeks...
Rejuvant
Supps report ad middle

Gut bacteria start-up exits stealth with unique data

Wild Biotech plans to use database of more than 1,200 gut microbes to pursue novel drugs for human diseases and enhance CRISPR editing. Wild Biotech,...

Age-related macular degeneration biotech raises $148m

Clinical-stage gene therapy company announces $148  million raised in Series C financing for age-related macular degeneration. London-based Gyroscope Therapeutics Limited, which focuses on treating diseases...

Cambrian Biopharma – CEO James Peyer Q&A

Longevity biotech exclusive Q&A with Cambrian Biopharma's CEO – hallmarks of aging and classifying aging as a disease. Dr James Peyer is Cambrian's CEO and...

Open platform to democratise longevity therapeutics R&D

VitaDAO aims to extend human lifespan “by researching, financing, and commercializing longevity therapeutics in an open and democratic manner.” An interesting new player has just...

Most popular

Cutting longevity drugs development from 15 years to one

Celeris bags €400k for creation of deep learning platform to support development of longevity drugs for Alzheimer's and other age-related diseases. With a focus on...

Longevity investing has “come of age” says MMC founder

McKenny-McFarlane Capital is focused on bridging the communication gap between longevity investing and longevity companies. An investment firm with its sights firmly locked on longevity...

Longevity companies to watch in 2021

As the world enters the new year with a vaccine and an increased focus on geroprotection, there’s much to look forward to. Research from the...

Andreessen Horowitz leads $7m seed funding: Bold

Digital health and wellness company bags $7 million in seed funding led by Andreessen Horowitz. Bold focuses on disease prevention and healthy aging. Using personalised and...
Supplement report

You might also like

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

New perspective in gerontology: epigenetic rejuvenation

Can biological age be set back by "making the clock tick backwards"? Scientists suggest that a partial phenotypic rejuvenation can be gained. Since the discovery...
Supps report ad middle